Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer

Volume: 5, Issue: 3, Pages: 182 - 190
Published: Feb 28, 2017
Abstract
Pancreatic cancer is a devastating disease that is largely refractory to currently available treatment strategies. Therapeutic resistance is partially attributed to the dense stromal reaction of pancreatic ductal adenocarcinoma tumors that includes a pervasive infiltration of immunosuppressive (M2) macrophages. Nab-paclitaxel (trade name Abraxane) is a nanoparticle albumin-bound formulation of paclitaxel that, in combination with gemcitabine, is...
Paper Details
Title
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Published Date
Feb 28, 2017
Volume
5
Issue
3
Pages
182 - 190
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.